Verastem (VSTM) Reports Q3 Loss, Tops Revenue Estimates

Core Viewpoint - Verastem reported a quarterly loss of $1.35 per share, significantly worse than the Zacks Consensus Estimate of a loss of $0.51, marking an earnings surprise of -164.71% [1] - The company achieved revenues of $11.24 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 82.80%, compared to zero revenues a year ago [2] Financial Performance - The loss per share increased from $0.60 a year ago to $1.35 this quarter, indicating a worsening financial situation [1] - Over the last four quarters, Verastem has only surpassed consensus EPS estimates once [2] Stock Performance - Verastem shares have increased approximately 91.5% since the beginning of the year, outperforming the S&P 500's gain of 16.5% [3] - The stock currently holds a Zacks Rank 2 (Buy), suggesting it is expected to outperform the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.42 on revenues of $22.07 million, and for the current fiscal year, it is -$2.44 on revenues of $18.75 million [7] - The outlook for the industry, specifically the Medical - Biomedical and Genetics sector, is favorable, ranking in the top 39% of over 250 Zacks industries [8]